Benzinga | Feb 4, 2021 08:41AM EST

Petros Pharmaceuticals Establishes Steering Committee To Expand Into Non-Rx Status For Stendra

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Petros or the Company) (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced that it has formed a steering committee to develop expanded patient access initiatives, including non-prescription or Over the Counter (OTC) status strategies, for its STENDRA(r) (avanafil) product, an oral medication used in the treatment of erectile dysfunction (ED). The committee will build upon more than 2 years of work conducted by the Company to pursue direct to consumer self-care mechanisms for increased engagement and control over their erectile health.